Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Glenmark Pharmaceuticals LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:532296NSE Symbol: GLENMARKP/E(TTM):30.82
ISIN Demat:INE935A01035Div & Yield %:0.13EPS(TTM):61.81
Book Value(Rs):868.3164333Market Cap ( Cr.):53763.49Face Value(Rs):1
    Change Company 
( In Cr)
 Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
INCOME :      
Sales Turnover 7891.128220.668141.587567.936712.636304.87
Excise Duty0.000.000.000.000.000.00
Net Sales7891.128220.668141.587567.936712.636304.87
Other Income 6238.36985.941044.96470.13625.34954.61
Stock Adjustments 103.0731.3716.13-5.24-48.77-471.81
Total Income14232.559237.979202.678032.827289.206787.67
EXPENDITURE :      
Raw Materials 3313.193427.073474.662944.532617.221887.15
Power & Fuel Cost104.9295.0991.3480.4990.7682.99
Employee Cost 1434.781346.511193.201107.401072.33969.98
Other Manufacturing Expenses 375.32304.66297.44267.26230.03218.75
Selling and Administration Expenses 1199.171246.101062.89914.37977.77992.83
Miscellaneous Expenses 325.15855.71349.97358.30371.53353.89
Less: Pre-operative Expenses Capitalised0.000.000.000.000.000.00
Total Expenditure6752.527275.136469.505672.355359.634505.58
Operating Profit7480.021962.842733.182360.471929.572282.08
Interest 277.11206.82236.04265.90256.39223.81
Gross Profit7202.911756.022497.142094.571673.182058.27
Depreciation202.16184.15159.70150.82138.54106.28
Profit Before Tax7000.751571.872337.441943.751534.641951.99
Tax1049.99386.93411.08343.62269.24383.50
Fringe Benefit tax0.000.000.000.000.000.00
Deferred Tax783.46-23.83-71.42-49.31-89.14-53.61
Reported Net Profit5167.291208.771997.791649.451354.551622.11
Extraordinary Items 3742.26-369.56354.0259.8714.43277.16
Adjusted Net Profit1425.031578.331643.771589.581340.121344.95
Adjst. below Net Profit -4.760.631.612.48-5.42-3.54
P & L Balance brought forward16002.8214863.9612921.8611340.4710059.388508.84
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 77.2270.5457.3070.5468.0368.03
P & L Balance carried down21088.1316002.8214863.9612921.8611340.4710059.38
Dividend0.000.000.000.000.000.00
Preference Dividend0.000.000.000.000.000.00
Equity Dividend %250.00250.00250.00250.00250.00200.00
Earnings Per Share-Unit Curr183.1142.8470.8058.4648.0057.49
Earnings Per Share(Adj)-Unit Curr183.1142.8470.8058.4648.0057.49
Book Value-Unit Curr814.01633.57593.21524.84468.73423.22